ABBV is expected to post a strong Q1, with neuroscience sales led by Botox and Vraylar projected to rise 22%. Newer drugs are helping offset declines in legacy treatments, supporting the outlook for the quarter. The update is favorable for earnings expectations and may modestly support the stock.
ABBV is expected to post a strong Q1, with neuroscience sales led by Botox and Vraylar projected to rise 22%. Newer drugs are helping offset declines in legacy treatments, supporting the outlook for the quarter. The update is favorable for earnings expectations and may modestly support the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.42
Ticker Sentiment
